Protective Effects of Bosentan via Endothelin Receptor Antagonism in Experimental Ischemia-Reperfusion Injury in the Lower Limb of Rats
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s510885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Hüseyin Demirtaş und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gazi University, Faculty of Medicine, Department of Cardiovascular Surgery, Ankara, Turkey. Hauptthemen laut MEDLINE: Bosentan, Reperfusion Injury, Endothelin Receptor Antagonists, Lower Extremity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
This study aimed to evaluate the protective effects of bosentan, a dual endothelin receptor antagonist, against skeletal muscle ischemia-reperfusion injury (IRI) in rats.
Methods
A total of 24 male Wistar Albino rats were divided into four groups: control (C, n=6), bosentan-treated (B, n=6), ischemia-reperfusion (IR, n=6), and bosentan plus ischemia-reperfusion (B+IR, n=6). Bosentan (10 mg/kg) was administered 30 minutes prior to reperfusion. In the IR and B+IR groups, ischemia was induced using vascular bulldog clamps for 45 minutes, followed by 120 minutes of reperfusion.
Results
Histological and biochemical assessments revealed significant differences among the groups. The disorganization and degeneration scores of the muscle cells in the B+IR group were significantly lower than those in the IR group (P = 0.001). The degree of interstitial edema in the IR group was markedly more severe than in the C and B groups (all P < 0.001), while the interstitial edema score in the B+IR group was significantly lower than that in the IR group (P < 0.001). The total muscle injury scores were markedly reduced in the B+IR group compared to the IR group (P < 0.001). Biochemically, TAS levels were significantly higher in the B+IR group compared to the IR group (1.03 ± 0.18 vs 0.59 ± 0.10 mmol/L, P = 0.016). Conversely, TOS (1.97 ± 0.39 vs 2.86 ± 0.43 IU/mg, P < 0.001) and OSI levels (P < 0.001) were significantly lower in the B+IR group. Additionally, paraoxonase (PON-1) enzyme activity was significantly reduced in the B+IR group compared to the IR group (P < 0.001). These findings suggest that bosentan exerts its protective effects by antagonizing endothelin-1 receptors, thereby mitigating vasoconstriction, oxidative stress, and inflammation. The observed reductions in muscle cell disorganization, interstitial edema, hemorrhage, neutrophil infiltration and oxidative stress markers underscore bosentan's potential as a therapeutic agent for managing ischemia-reperfusion injury.
Conclusion
Bosentan demonstrates significant protective effects against skeletal muscle IRI by reducing oxidative stress and inflammation through endothelin receptor antagonism. These findings underscore bosentan's potential as a therapeutic agent for mitigating ischemia-reperfusion injury in vascular surgeries and managing critical limb ischemia in clinical settings. Further research is warranted to explore the long-term effects of bosentan on muscle recovery and systemic health following ischemia-reperfusion injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gazi University, Faculty of Medicine, Department of Cardiovascular Surgery, Ankara, Turkey.
- Erzurum City Hospital, Department of Cardiovascular Surgery, Erzurum, Turkey.
- Gazi University, Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey.
- Gazi University, Neuroscience and Neurotechnology Center of Excellence, NÖROM, Ankara, Turkey.
- Kutahya Health Sciences University, Faculty of Medicine, Department of Physiology, Kutahya, Turkey.
- Gazi University, Faculty of Medicine, Department of Anesthesiology and Reamination, Ankara, Turkey.
ORCID-Profile: Hüseyin Demirtaş, Abdullah Özer, Mehmet Burak Gülcan, Ayşegül Küçük, Esra Tekin, Ali Doğan Dursun, Aslı Dağlı, Mustafa Arslan
Zitieren
APA
Demirtaş, H., Özer, A., Gülcan, M. B., Yığman, Z., Küçük, A., Tekin, E., Ünal, Y., Dursun, A. D., Dağlı, A., & Arslan, M. (2025). Protective Effects of Bosentan via Endothelin Receptor Antagonism in Experimental Ischemia-Reperfusion Injury in the Lower Limb of Rats. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s510885
Vancouver
Demirtaş H, Özer A, Gülcan MB, Yığman Z, Küçük A, Tekin E, et al. Protective Effects of Bosentan via Endothelin Receptor Antagonism in Experimental Ischemia-Reperfusion Injury in the Lower Limb of Rats. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s510885
BibTeX
@article{Demirta2025,
author = {Demirtaş, Hüseyin and Özer, Abdullah and Gülcan, Mehmet Burak and Yığman, Zeynep and Küçük, Ayşegül and Tekin, Esra and Ünal, Yusuf and Dursun, Ali Doğan and Dağlı, Aslı and Arslan, Mustafa},
title = {Protective Effects of Bosentan via Endothelin Receptor Antagonism in Experimental Ischemia-Reperfusion Injury in the Lower Limb of Rats},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s510885}
}
EUVIMED